Plöger, Gerlinde FAbrahamsson, BertilCristofoletti, RodrigoGroot, D I R K WLangguth, PeterMehta, Mehul UParr, AlanPolli, James EShah, Vinod PTajiri, TomokazuDressman, Jennifer B2018-04-192018-04-192018-03-20Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride. 2018 J Pharm Sci1520-60172957174010.1016/j.xphs.2018.03.009http://hdl.handle.net/10029/621819Literature data relevant to the decision to waive in vivo bioequivalence testing for the approval of generic immediate release solid oral dosage forms of proguanil hydrochloride are reviewed. To clarify the Biopharmaceutics Classification System (BCS) classification, experimental solubility and dissolution studies were also carried out. The antimalarial proguanil hydrochloride, effective via the parent compound proguanil and the metabolite cycloguanil, is not considered to be a narrow therapeutic index drug. Proguanil hydrochloride salt was shown to be highly soluble according to the FDA, WHO and EMA guidelines, but data for permeability are inconclusive. Therefore, proguanil hydrochloride is conservatively classified as a BCS Class 3 substance. In view of this information and the assessment of risks associated with a false positive decision, a BCS-based biowaiver approval procedure can be recommended for orally administered solid IR products containing proguanil hydrochloride, provided well-known excipients are used in usual amounts and provided the in vitro dissolution of the test and reference products is very rapid (85% or more are dissolved in 15 minutes at pH 1.2, 4.5 and 6.8) and is performed according to the current requirements for BCS-based biowaivers.eninfo:eu-repo/semantics/closedAccessArticleTijdschrift Tijdschrift J Pharm Sci 2018; 107(7):1761-72